Clinical trial • Phase III • Oncology
DOMVANALIMAB for Gastric adenocarcinoma | Gastroesophageal junction adenocarcinoma | Esophageal adenocarcinoma
Phase III trial of DOMVANALIMAB for Gastric adenocarcinoma | Gastroesophageal junction adenocarcinoma | Esophageal adenocarcinoma.
Overview
- Trial Therapeutic Area
- Oncology
- Trial Disease
- Gastric adenocarcinoma | Gastroesophageal junction adenocarcinoma | Esophageal adenocarcinoma
- Trial Stage
- Phase III
- Drug Modality
- Monoclonal antibody | Small molecule
Key dates
- Initial CTIS Submission Date
- 31-07-2024
- First CTIS Authorization Date
- 29-08-2024
Trial design
Randomised, open-label, active comparator: nivolumab + folfox/capox (pi choice). participants in this arm will receive nivolumab q2w and folfox q2w or nivolumab q3w + capox q3w. (dose amounts not specified in provided record.)-controlled, adaptive Phase III trial in Portugal, Lithuania, Romania and others.
- Randomised
- Yes
- Open Label
- Yes
- Comparator
- Active Comparator: nivolumab + FOLFOX/CAPOX (PI Choice). Participants in this arm will receive nivolumab Q2W and FOLFOX Q2W or nivolumab Q3W + CAPOX Q3W. (Dose amounts not specified in provided record.)
- Adaptive
- True, a planned interim analysis reviewed by the Independent Data Monitoring Committee (IDMC) was performed; the IDMC recommended stopping the study after the interim analysis (IDMC meeting 09 December 2025) for futility.
- Biomarker Stratified
- True, PD-L1 (strata described in objectives: high PD-L1 expression; positive PD-L1 expression; all randomized participants)
- Target Sample Size
- 563
- Trial Duration For Participant
- 730
Eligibility
Recruits 563 isVulnerablePopulationSelected = true; participants must be capable of giving signed informed consent: "Capable of giving signed informed consent which is in compliance with the requirements and restrictions listed in the informed consent form (ICF) and in protocol." No additional assent or surrogate consent arrangements are described in the available record..
- Vulnerable Population
- isVulnerablePopulationSelected = true; participants must be capable of giving signed informed consent: "Capable of giving signed informed consent which is in compliance with the requirements and restrictions listed in the informed consent form (ICF) and in protocol." No additional assent or surrogate consent arrangements are described in the available record.
Inclusion criteria
- {"criterion_text":"- Age >= 18 years at the time of signing the informed consent."}
- {"criterion_text":"- Capable of giving signed informed consent which is in compliance with the requirements and restrictions listed in the informed consent form (ICF) and in protocol."}
- {"criterion_text":"- Histologically confirmed diagnosis of locally advanced unresectable or metastatic gastric, GEJ, or esophageal adenocarcinoma."}
- {"criterion_text":"- Eastern Cooperative Oncology Group (ECOG) Performance Score of 0-1."}
- {"criterion_text":"- At least one measurable target lesion per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1."}
Exclusion criteria
- {"criterion_text":"- Underlying medical or psychiatric conditions that, in the investigator's or sponsor's opinion, will make the administration of study-specified therapy hazardous, including but not limited to: 1. Interstitial lung disease, including history of interstitial lung disease or non-infectious pneumonitis. Active viral, bacterial, or fungal infections requiring parenteral treatment within 14 days of randomization, 2. Clinically significant cardiovascular disease, such as New York Heart Association Class II or greater cardiac disease or cerebrovascular accident within 3 months prior to randomization, unstable angina, or new onset angina within 3 months prior to randomization, myocardial infarction within 6 months prior to randomization, or unstable arrhythmia within 3 months prior to randomization, 3. History of prior solid-organ transplantation, including allogenic bone marrow transplantation, 4. Dementia, psychiatric, or substance abuse disorders that would interfere with satisfying the requirements of the trial."}
- {"criterion_text":"- Known human epidermal growth factor receptor 2 (HER-2) positive tumor."}
- {"criterion_text":"- Known untreated, symptomatic, or actively progressing central nervous system (CNS) (brain) metastases. Participants with leptomeningeal metastases are excluded from enrollment."}
- {"criterion_text":"- Received prior systemic treatment for locally advanced unresectable or metastatic gastric, GEJ, or esophageal adenocarcinoma."}
- {"criterion_text":"- Disease progression within 6 months of neoadjuvant or adjuvant chemotherapy."}
Endpoints
Primary endpoints
- {"endpoint_text":"- OS is defined as the length of time from date of randomization until the date of death from any cause","definition_or_measurement_approach":"OS is defined as the length of time from date of randomization until the date of death from any cause."}
Secondary endpoints
- {"endpoint_text":"- PFS is defined as the time from date of randomization until disease progression or death from any cause, whichever comes first, as measured per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as assessed by the investigator","definition_or_measurement_approach":"Time from date of randomization until disease progression or death, whichever occurs first, measured per RECIST v1.1 as assessed by the investigator."}
- {"endpoint_text":"- Time to first symptom deterioration in the FACT-Ga gastric cancer subscale.","definition_or_measurement_approach":"Time to first deterioration in the FACT-Ga gastric cancer subscale."}
- {"endpoint_text":"- Objective response rate (ORR) is defined as the proportion of participants who have achieved confirmed complete response (CR) or confirmed partial response (PR) to study therapy as assessed by the investigator according to RECIST 1.1","definition_or_measurement_approach":"Proportion of participants with confirmed CR or PR assessed by investigator per RECIST v1.1."}
- {"endpoint_text":"- Duration of response (DOR) is measured from the time of first confirmed response (CR or PR as measured by RECIST v1.1) as assessed by the investigator, until the date of first documented disease progression or death, whichever comes first.","definition_or_measurement_approach":"Measured from first confirmed CR/PR (per RECIST v1.1) to first documented progression or death, whichever occurs first."}
- {"endpoint_text":"- The incidence and severity of adverse events (AEs) and serious adverse events (SAEs), and any clinically meaningful trends in safety parameters","definition_or_measurement_approach":"Incidence and severity of AEs and SAEs captured and summarized; clinically meaningful trends in safety parameters evaluated."}
Recruitment
- Digital Remote Recruitment
- True, digital methods referenced include Scout Email Communication, Scout Study Brochure, ScoutPass Reloadable and ePRO/IRT (Signant Health) for electronic patient-reported outcomes and remote interactions.
- Planned Sample Size
- 563
- Recruitment Window Months
- 50
- Consent Approach
- Informed consent must be signed by the participant: "Capable of giving signed informed consent which is in compliance with the requirements and restrictions listed in the informed consent form (ICF) and in protocol." Subject information and ICF documents are available in multiple languages (English, Portuguese, Spanish, French, Greek, Hungarian, Lithuanian, Romanian, Italian, Polish, Russian and others shown in the document list). No separate assent/surrogate consent procedures are described in the available record.
Methods
- Site-based recruitment via participating hospitals and oncology centres listed in member state Part II submissions (trial sites across France, Greece, Hungary, Italy, Lithuania, Portugal, Romania, Spain, Poland).
- Third-party patient outreach and engagement via Scout Clinical (materials identified: Scout Email Communication, Scout Study Brochure, ScoutPass reloadable) and related 'Scout' patient-facing materials; third-party involvement for patient reimbursement.
- Investigator/clinic-led approaches including Investigator Letters (K1 Investigator Letter documents) provided to sites.
Geography
- Total Number Of Sites
- Unknown
- Total Number Of Participants
- Unknown
Portugal
- Latest Decision Or Authorization Date
- 21-04-2025
- Number Of Sites
- 3
- Number Of Participants
- 11
Sites
- Site Name
- Champalimaud Clinical Centre
- Contact Person Name
- Nuno Couto
- Contact Person Email
- nuno.couto@fundacaochampalimaud.pt
- Site Name
- Instituto Portugues De Oncologia Do Porto Francisco Gentil E.P.E.
- Department Name
- Medical Oncology
- Contact Person Name
- Nuno Sousa
- Contact Person Email
- nuno.sousa@ipoporto.min-saude.pt
- Site Name
- Unidade Local De Saude De Coimbra E.P.E.
- Department Name
- Medical Oncology
- Contact Person Name
- Edgar Pratas
- Contact Person Email
- 10557@chuc.min-saude.pt
Lithuania
- Latest Decision Or Authorization Date
- 19-05-2025
- Number Of Sites
- 4
- Number Of Participants
- 9
Sites
- Site Name
- Nacionalinis vezio institutas
- Department Name
- Nacionalinis Vėžio Institutas
- Contact Person Name
- Edita Baltruskeviciene
- Contact Person Email
- edita.baltruskeviciene@nvi.lt
- Site Name
- Klaipedos universiteto ligonine VšĮ
- Department Name
- Klaipedos Universitetine Ligonine
- Contact Person Name
- Alvydas Cesas
- Contact Person Email
- a.cesas@kul.lt
- Site Name
- Vilniaus Universiteto Ligonine Santaros Klinikos Vsi
- Department Name
- Vilniaus Universiteto Ligoninė Santariškių Klinikos
- Contact Person Name
- Skaiste Tulyte
- Contact Person Email
- skaiste.tulyte@santa.lt
- Site Name
- Lietuvos sveikatos mokslu universiteto ligonine Kauno klinikos
- Department Name
- Kauno Klinikos
- Contact Person Name
- Rasa Janciauskiene
- Contact Person Email
- rasa.janciauskiene@kaunoklinikos.lt
Romania
- Latest Decision Or Authorization Date
- 28-04-2025
- Number Of Sites
- 8
- Number Of Participants
- 49
Sites
- Site Name
- Centrul De Oncologie SF Nectarie S.R.L.
- Department Name
- Medical Oncology
- Contact Person Name
- Michael Schenker
- Contact Person Email
- mike_schenker@yahoo.com
- Site Name
- Sigmedical Services S.R.L.
- Department Name
- Medical Oncology
- Contact Person Name
- Doina Elena Ganea
- Contact Person Email
- motan_doina@yahoo.com
- Site Name
- Radiotherapy Center Cluj S.R.L.
- Department Name
- Medical Oncology
- Contact Person Name
- Andrei Ungureanu
- Contact Person Email
- andrei.ungureanu@amethyst-radiotherapy.com
- Site Name
- Spitalul Judetean De Urgenta Dr. Constantin Opris Baia Mare
- Department Name
- Medical Oncology
- Contact Person Name
- Dumitru Filip
- Contact Person Email
- filipd1@yahoo.com
- Site Name
- Medisprof S.R.L.
- Department Name
- Medical Oncology
- Contact Person Name
- Anghel-Adrian Udrea
- Contact Person Email
- adrianudrea@medisprof.ro
- Site Name
- Institute Of Oncology Prof. Dr. Ion Chiricuta Cluj-Napoca
- Department Name
- Medical Oncology
- Contact Person Name
- Alina Muntean
- Contact Person Email
- muntean.alina@yahoo.fr
- Site Name
- Centrul De Oncologie-Euroclinic S.R.L.
- Department Name
- Medical Oncology
- Contact Person Name
- Constantin Volovat
- Contact Person Email
- cvolovat@yahoo.com
- Site Name
- Institutul Clinic Fundeni
- Department Name
- Medical Oncology
- Contact Person Name
- Adina Emilia Croitoru
- Contact Person Email
- adina.croitoru09@yahoo.com
Hungary
- Latest Decision Or Authorization Date
- 22-04-2025
- Number Of Sites
- 4
- Number Of Participants
- 1
Sites
- Site Name
- Del-Pesti Centrumkorhaz Orszagos Hematologiai Es Infektologiai Intezet
- Department Name
- Onkológiai Centrum
- Contact Person Name
- György Bodoky
- Contact Person Email
- bodoky.gyorgy@dpckorhaz.hu
- Site Name
- Orszagos Onkologiai Intezet
- Department Name
- Mellkasi és Hasüregi Daganatok és Klinikai Farmakológiai Osztály
- Contact Person Name
- Pintér Tamás
- Contact Person Email
- tpinter@gmail.com
- Site Name
- Bacs-Kiskun Varmegyei Oktatokorhaz
- Department Name
- Onkoradiológiai Központ
- Contact Person Name
- Kocsis Judit
- Contact Person Email
- kocsisjucidr@gmail.com
- Site Name
- University Of Pecs
- Department Name
- Onkoterápiás Intézet
- Contact Person Name
- Szabolcs Bellyei
- Contact Person Email
- bellyeisz@gmail.com
France
- Latest Decision Or Authorization Date
- 13-05-2026
- Number Of Sites
- 11
- Number Of Participants
- 31
Sites
- Site Name
- Centre Hospitalier Regional Et Universitaire De Brest
- Department Name
- Medical Oncology
- Contact Person Name
- Jean-Philippe Metges
- Contact Person Email
- jean-philippe.metges@chu-brest.fr
- Site Name
- Institut Regional Du Cancer De Montpellier
- Department Name
- Medical Oncology
- Contact Person Name
- Antoine Adenis
- Contact Person Email
- antoine.adenis@icm.unicancer.fr
- Site Name
- Institut Gustave Roussy
- Department Name
- Department of Cancer Medicine
- Contact Person Name
- Valérie Boige
- Contact Person Email
- valerie.boige@gustaveroussy.fr
- Site Name
- Institut Bergonie
- Department Name
- Medical Oncology
- Contact Person Name
- Lola Jade Palmieri
- Contact Person Email
- l.palmieri@bordeaux.unicancer.fr
- Site Name
- CARIO Centre Armoricain de Radiotherapie D'Imagerie medicale et D'Oncologie
- Department Name
- Medical Oncology
- Contact Person Name
- Jérôme Martin-Babau
- Contact Person Email
- j.martin@cario-sante.fr
- Site Name
- Centre Hospitalier Universitaire De Toulouse
- Department Name
- Digestive Medical oncology
- Contact Person Name
- Rosine Guimbaud
- Contact Person Email
- guimbaud.r@chu-toulouse.fr
- Site Name
- Hopital Huriez
- Department Name
- Medical Oncology
- Contact Person Name
- Anne Ploquin
- Contact Person Email
- anne.ploquin@chu-lille.fr
- Site Name
- Centre Leon Berard
- Department Name
- Medical Oncology
- Contact Person Name
- Clélia Coutzac
- Contact Person Email
- clelia.coutzac@lyon.unicancer.fr
- Site Name
- Centre Hospitalier Universitaire De Poitiers
- Department Name
- Hepato- gastroenterology department
- Contact Person Name
- David Tougeron
- Contact Person Email
- david.tougeron@chu-poitiers.fr
- Site Name
- Centre Hospitalier Regional De Marseille
- Department Name
- Digestive Oncology, Hepato- gastroenterology department
- Contact Person Name
- Muriel Duluc
- Contact Person Email
- muriel.duluc@ap-hm.fr
- Site Name
- Centre Francois Baclesse
- Department Name
- Medical Oncology
- Contact Person Name
- Marie-Pierre Galais
- Contact Person Email
- mp.galais@baclesse.fr
Greece
- Latest Decision Or Authorization Date
- 17-04-2026
- Number Of Sites
- 3
- Number Of Participants
- 9
Sites
- Site Name
- Metropolitan Hospital
- Department Name
- 1st Oncology Clinic
- Contact Person Name
- Dimitrios Bafaloukos
- Contact Person Email
- dbafaloukos@metropolitan-hospital.gr
- Site Name
- Athens Medical Center S.A.
- Department Name
- Oncology Department
- Contact Person Name
- Michalis Karamouzis
- Contact Person Email
- michalis.karamouzis@gmail.com
- Site Name
- General Oncological Hospital Of Kifissia Agioi Anargyroi
- Department Name
- Department of Medical Oncology
- Contact Person Name
- Eleni Res
- Contact Person Email
- nellieres@yahoo.gr
Italy
- Latest Decision Or Authorization Date
- 15-04-2026
- Number Of Sites
- 5
- Number Of Participants
- 19
Sites
- Site Name
- Istituto Europeo Di Oncologia S.r.l.
- Department Name
- Divisione di Oncologia Medica Gastrointestinale e Tumori Neuroendocrini
- Contact Person Name
- Lorenzo Gervaso
- Contact Person Email
- lorenzo.gervaso@ieo.it
- Site Name
- Humanitas Mirasole S.p.A.
- Department Name
- Department of Oncology and Hematology
- Contact Person Name
- Armando Santoro
- Contact Person Email
- armando.santoro@cancercenter.humanitas.it
- Site Name
- Azienda Unita Sanitaria Locale Della Romagna
- Department Name
- UOC Oncologia Ravenna Lugo Faenza - Ravenna
- Contact Person Name
- Stefano Tamberi
- Contact Person Email
- stefano.tamberi@auslromagna.it
- Site Name
- Azienda Ospedaliero Universitaria Careggi
- Department Name
- Department of Medical Oncology 1
- Contact Person Name
- Lorenzo Antonuzzo
- Contact Person Email
- antonuzzol@aoucareggi.toscana.it
- Site Name
- Ospedale San Raffaele S.r.l.
- Department Name
- Dipartimento di Oncologia Medica
- Contact Person Name
- Silvia Foti
- Contact Person Email
- foti.silvia@hsr.it
Spain
- Latest Decision Or Authorization Date
- 17-04-2026
- Number Of Sites
- 8
- Number Of Participants
- 13
Sites
- Site Name
- Hospital Universitario Hm Sanchinarro
- Department Name
- Oncology
- Contact Person Name
- Rafael Alvarez Gallego
- Contact Person Email
- ralvarezgallego@hmhospitales.com
- Site Name
- Hospital Universitario Miguel Servet
- Department Name
- Medical Oncology
- Contact Person Name
- Roberto Pazo Cid
- Contact Person Email
- rpazo@salud.aragon.es
- Site Name
- Hospital Universitari Vall D Hebron
- Department Name
- Medical Oncology
- Contact Person Name
- Daniel Acosta
- Contact Person Email
- dacosta@vhio.net
- Site Name
- Hospital Universitario Marques De Valdecilla
- Department Name
- Medical Oncology
- Contact Person Name
- Fernando Rivera Herrero
- Contact Person Email
- fernando.rivera@scsalud.es
- Site Name
- Hospital Universitario Ramon Y Cajal
- Department Name
- Medical Oncology
- Contact Person Name
- Federico Longo Munoz
- Contact Person Email
- fedelongomunoz@hotmail.com
- Site Name
- Hospital Clinico Universitario De Valencia
- Department Name
- Medical Oncology
- Contact Person Name
- Tania Fleitas Kanonnikoff
- Contact Person Email
- tfleitask@gmail.com
- Site Name
- Institut Catala D'oncologia
- Department Name
- Medical Oncology
- Contact Person Name
- Mariona Calvo-Campos
- Contact Person Email
- mcalvo@iconcologia.net
- Site Name
- Hospital Universitario Marques De Valdecilla (duplicate listing)
Poland
- Latest Decision Or Authorization Date
- 20-04-2026
- Number Of Sites
- 2
- Number Of Participants
- 10
Sites
- Site Name
- Centrum Onkologii Ziemi Lubelskiej Im. Sw. Jana Z Dukli
- Department Name
- I Chemotherapy Day Unit
- Contact Person Name
- Agata Chrzanowska- Kapica
- Contact Person Email
- achrzanowska@cozl.eu
- Site Name
- Narodowy Instytut Onkologii Im. Marii Skłodowskiej- Curie - Państwowy Instytut Badawczy
- Department Name
- Department of Oncology and Radiotherapy
- Contact Person Name
- Lucjan Wyrwicz
- Contact Person Email
- lucjan.wyrwicz@nio.gov.pl
Sponsor
Primary sponsor
- Full Name
- Arcus Biosciences Inc.
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- United States
Contract research organisations
- Name
- Icon Clinical Research Limited
- Responsibilities
- [{"id":929261,"code":"4"}]
- Name
- PRA Hellas CRO A.E.
- Responsibilities
- [{"id":929268,"code":"1"},{"id":929269,"code":"12"}]
- Name
- Syneos Health Inc.
- Responsibilities
- [{"id":929249,"code":"15","value":"Zimberelimab PK"},{"id":929250,"code":"4"}]
- Name
- PPD (UK) Limited
- Responsibilities
- [{"id":929265,"code":"8"}]
- Name
- Veranex Inc.
- Responsibilities
- [{"id":929264,"code":"10"}]
Third parties
- {"country":"United States","full_name":"Scout Clinical","duties_or_roles":"Clinical Trial Patient Reimbursement","organisation_type":"Hospital/Clinic/Other health care facility"}
- {"country":"Hungary","full_name":"Precision for Medicine (HU) Kft.","duties_or_roles":"","organisation_type":"Pharmaceutical company"}
- {"country":"United States","full_name":"Veranex Inc.","duties_or_roles":"","organisation_type":"Pharmaceutical company"}
- {"country":"Ireland","full_name":"Icon Clinical Research Limited","duties_or_roles":"","organisation_type":"Pharmaceutical company"}
- {"country":"United States","full_name":"Ventana Medical Systems Inc.","duties_or_roles":"Tumor biopsy - leftover samples","organisation_type":"Pharmaceutical company"}
- {"country":"United States","full_name":"United Biosource LLC","duties_or_roles":"","organisation_type":"Pharmaceutical company"}
- {"country":"United States","full_name":"Signant Health LLC","duties_or_roles":"ePRO/IRT","organisation_type":"Pharmaceutical company"}
- {"country":"Belgium","full_name":"CellCarta","duties_or_roles":"Tumor biopsy - during study","organisation_type":"Laboratory/Research/Testing facility"}
- {"country":"United States","full_name":"Syneos Health Inc.","duties_or_roles":"Zimberelimab PK","organisation_type":"Pharmaceutical company"}
- {"country":"Greece","full_name":"PRA Hellas CRO A.E.","duties_or_roles":"","organisation_type":"Pharmaceutical company"}
- {"country":"United States","full_name":"Alliance Pharma Inc.","duties_or_roles":"Zimberelimab ADA","organisation_type":"Pharmaceutical company"}
- {"country":"United States","full_name":"Suvoda LLC","duties_or_roles":"","organisation_type":"Non-Pharmaceutical company"}
- {"country":"United Kingdom","full_name":"PPD (UK) Limited","duties_or_roles":"","organisation_type":"Pharmaceutical company"}
- {"country":"Switzerland","full_name":"Clario","duties_or_roles":"","organisation_type":"Health care"}
- {"country":"United States","full_name":"Mosaic Laboratories LLC","duties_or_roles":"Leftover samples","organisation_type":"Pharmaceutical company"}
- {"country":"United States","full_name":"Medidata Solutions Inc.","duties_or_roles":"","organisation_type":"Non-Pharmaceutical company"}
- {"country":"United States","full_name":"Charles River Laboratories Inc.","duties_or_roles":"Domvanalimab PK & ADA","organisation_type":"Pharmaceutical company"}
Investigational products
- Investigational Product Name
- DOMVANALIMAB
- Active Substance
- DOMVANALIMAB
- Modality
- Monoclonal antibody
- Routes Of Administration
- Concentrate for solution for infusion (intravenous infusion)
- Route
- IV (concentrate for solution for infusion)
- Authorisation Status
- 1
- Frequency
- Once every 4 weeks (Q4W) or once every 3 weeks (Q3W) as described for combination schedule
- Investigational Product Name
- Zimberelimab
- Active Substance
- ZIMBERELIMAB
- Modality
- Monoclonal antibody
- Routes Of Administration
- Concentrate for solution for infusion (intravenous infusion)
- Route
- IV (concentrate for solution for infusion)
- Authorisation Status
- 1
- Frequency
- Once every 4 weeks (Q4W) or once every 3 weeks (Q3W) as described for combination schedule
- Investigational Product Name
- NIVOLUMAB
- Active Substance
- NIVOLUMAB
- Modality
- Monoclonal antibody
- Routes Of Administration
- Concentrate for solution for infusion (intravenous infusion)
- Route
- IV (concentrate for solution for infusion)
- Authorisation Status
- 2
- Frequency
- Q2W or Q3W (per comparator arm description)
- Investigational Product Name
- CAPECITABINE
- Active Substance
- CAPECITABINE
- Modality
- Small molecule
- Routes Of Administration
- Oral use (tablet)
- Route
- Oral
- Authorisation Status
- 2
- Investigational Product Name
- FLUOROURACIL
- Active Substance
- FLUOROURACIL
- Modality
- Small molecule
- Routes Of Administration
- Solution for injection/infusion
- Route
- IV or injection
- Authorisation Status
- 2
- Investigational Product Name
- OXALIPLATIN
- Active Substance
- OXALIPLATIN
- Modality
- Small molecule
- Routes Of Administration
- Concentrate for solution for infusion
- Route
- IV (infusion)
- Authorisation Status
- 2
- Investigational Product Name
- CALCIUM FOLINATE
- Active Substance
- CALCIUM FOLINATE
- Modality
- Small molecule
- Routes Of Administration
- Solution for injection
- Route
- Injection
- Authorisation Status
- 2
- Combination Treatment
- Yes
Related trials
Other published trials that may interest you.
- SACITUZUMAB TIRUMOTECAN for Gastric adenocarcinoma | Gastroesophageal junction adenocarcinoma | Esophageal adenocarcinoma
- GDC-9545 for Locally advanced or metastatic estrogen receptor-positive breast cancer
- Abemaciclib for Stage IV lung cancer | Breast cancer
- BGB-43395 for Advanced or metastatic solid tumors | Hormone receptor positive HER2 negative breast cancer
- AZD9833 for Estrogen receptor-positive HER2-negative advanced breast cancer